Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Recruiting · NCT04991103 · Registry updated 2025-12-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2025-12-31 | NCT04991103 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Alabama at Birmingham | 467 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | United States | 247 |